BrainStorm reports FY2025 net loss $10.3M; secures $2M post-year-end for Phase 3b

BRAINSTORM CELL THERAPEUTICS INC.

Cash, equivalents, restricted cash $0.3M at Dec 31, 2025; raised $2M in Feb 2026 private placements.
Net loss $10.3M ($1.11/share) vs $11.6M ($2.31/share) in 2024; R&D spend $4.2M, G&A $5.8M.
FDA cleared Phase 3b ENDURANCE study of NurOwn for ALS; ~200 participants, SPA and CMC aligned.
Expanded Access Program: 5/10 patients alive, mean survival ~84 months; all 10 exceeded 5-year survival.
Company highlights $2M strategic financing as catalyst for share re-rating and cash runway for operations.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BRAINSTORM CELL THERAPEUTICS INC. reported the full year ended December 31, 2025 results: net income Net loss for the twelve months ended December 31, 2025, was approximately $10.3 million, EPS Net loss per share for the twelve months ended December 31, 2025, and 2024 was $1.11 and $2.31, respectively.

Period: the full year ended December 31, 2025
Net income: Net loss for the twelve months ended December 31, 2025, was approximately $10.3 million
EPS: Net loss per share for the twelve months ended December 31, 2025, and 2024 was $1.11 and $2.31, respectively
Result: reported results

Exact text from the filing

On March 31, 2026, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the year ended December 31, 2025.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-037760

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.